Central retinal thickness was reduced in some patients with DME or wet AMD after a change in anti-VEGF treatment, according to a poster presented at the virtual Association for Research in Vision and Ophthalmology meeting.
Sohel Somani, MD, FRCSC, and colleagues evaluated treatment outcomes in patients with neovascular age-related macular edema (AMD) and diabetic macular edema (DME) who were switched from Eylea (aflibercept, Regeneron) to ranibizumab pre-filled syringes (Genentech).
The PRECISE study, an ongoing, prospective, observational real-world study, enrolled 177 patients with
Uncategorized